Targeted cancer therapy stories

Aug 7, 2026

New Research Reveals Ferroptosis Vulnerability in FLT3-Mutated Acute Myeloid Leukemia, Advancing Treatment Options

A Nature Cell Biology study identifies a novel therapeutic vulnerability in acute myeloid leukemia with FLT3 mutations, showing that FLT3 inhibitors trigger ferroptosis in cancer cells. The findings complement ongoing advances in FLT3-ITD+ AML treatment, including improved minimal residual disease testing and updated clinical practice guidelines.

Aug 7, 20263 sources

Jun 9, 2026

GSK Acquires Nuvalent for $10.6 Billion to Expand Cancer Drug Portfolio

UK pharmaceutical giant GSK has entered an agreement to acquire U.S.-based cancer drugmaker Nuvalent for $10.6 billion, adding targeted cancer therapies to its portfolio in one of the year's largest biopharma acquisitions.

Jun 9, 20263 sources

Top claims

▪Minimal residual disease measurements using FLT3-ITD-specific assays demonstrate potential prognostic utility in the clinical management of patients with FLT3-ITD-positive acute myeloid leukemia.
▪Results from the QuANTUM First trial showed that a larger share of patients in composite complete remission had undetectable minimal residual disease in the quizartinib arm than in the placebo arm (12.3% vs 7.0%).
▪Researchers found that dietary vitamin E, which attenuates ferroptosis, can markedly reduce the efficacy of the FLT3 inhibitor gilteritinib in acute myeloid leukemia models.

Subtopics

Drug Approval and Clinical Trials1 Pharma1

Related timelines